Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $139.3452W HIGH $184.90
Volume
3.01 M
Value Traded
353.44 M
Short % Float
1.94%
Days to Cover
3.7
+0.9%Week
+6.94%1 Month
-1.63%3 Month
+23.16%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
89.91 B
EPS (TTM)
6.86
P/E Ratio
25.43
Ent. Value
99.76 B
Total Shares
515.72 M
Float Shares
516.30 M
Insiders
0.08%
Institutions
77.31%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MMM Catalyst Timeline
Dated clinical, regulatory and corporate events for 3M Company
Catalyst Timeline
Dated clinical, regulatory & corporate events for 3M Company
55Total events
1Upcoming
19Tier-1 (high impact)
2019 to 2026Coverage
Upcoming catalysts 1
TBD
T2Equity Offering
Subscribe to view catalyst details
Event history 48
▲Partnership / LicenseCorporate
3M announces collaboration with GSEO to advance Expanded Beam Optical manufacturing and development
●IP Litigation RulingIP / Competition
Final approval of PFAS public water supplier settlement
▲Quarterly UpdateCorporate
Claimant participation in Combat Arms Earplugs litigation settlement on track to exceed 98% threshold
●Quarterly UpdateCorporate
3M reported full-year 2023 GAAP loss per share of $12.63 and adjusted EPS of $9.24
●Quarterly UpdateCorporate
3M provided full-year 2024 adjusted EPS guidance of $9.35-$9.75 and adjusted total sales growth of 0.25%-2.25%
▼Program DiscontinuationCorporate
PFAS manufacturing exit and discontinuation of use across product portfolio
●AcquisitionCorporate
PFAS Public Water Systems agreement received preliminary court approval
▼Restructuring LayoffsCorporate
Restructuring actions announced affecting ~6,000 positions globally
▼Restructuring LayoffsCorporate
Reduction of 2,500 global manufacturing roles announced in January 2023
▼Quarterly UpdateCorporate
Estimated Q4 2022 pre-tax charge of $0.7B to $1.0B related to PFAS exit
◆AcquisitionCorporate
Closing of merger between Neogen subsidiary and SpinCo expected promptly after exchange offer
◆AcquisitionCorporate
3M commences exchange offer for food safety business separation via Reverse Morris Trust with Neogen
●Timing GuidancePresentation
Affirming full-year 2019 organic growth and adjusted earnings expectations
Past FDA Catalysts and PDUFA Decisions
How MMM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 85%
Large Pharma(rank 559 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every MMM program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Goralski Christian T JROfficer (Group President) | Option | 1,288 8,259.28 held | $162.12 | 10/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MMM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 0.1 % | 210.00 K | 1.62 K |
MMM Institutional Ownership Trends
MMM Short Interest
Shares sold short, counted twice a month.
1.94%
Short % of Float
of tradable shares sold short
10.0M
Shares Sold Short
+3.7% vs prior count
3.7 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-06 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MMM ranks across every disease it competes in
Competitive Position is a premium feature
See how MMM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMMM News
-MMM
Oct 21, 20263M and AWS collaborate to advance optical connectivity innovation
3M and AWS have announced a strategic collaboration to deploy 3M's Expanded Beam Optical technology in AWS's data centers. This partnership aims to enhance optical connectivity and support over 500 jobs in the U.S. by 2027. 3M expects to invest nearly $0.5 billion into the U.S. economy through this initiative.
Read more →-MMM
Oct 20, 2026▲ +5.8%on this newsshared move
3M Reports Third-Quarter 2026 Results; Raises Full-Year EPS Guidance
3M reported third-quarter 2026 results with GAAP sales of $6.6 billion, reflecting a 1.0% increase year-on-year. The company raised its full-year adjusted EPS guidance to between $9.10 and $9.15, supported by a 12% rise in adjusted EPS to $2.50. Operating margins also improved, reaching 26.2%. Strong free cash flow of $1.2 billion was reported.
Read more →-MMM
Oct 19, 2026▲ +5.8%on this newsshared move
3M announces collaboration with GSEO to advance Expanded Beam Optical manufacturing and development
3M announced a collaboration with Genius Electronic Optical Co., Ltd. to enhance its Expanded Beam Optical (EBO) solutions. The partnership includes a strategic investment by 3M to acquire approximately 4.7% of GSEO's shares. This collaboration aims to support EBO commercialization and meet the rising demand from hyperscale data centers.
Read more →-MMM
Oct 14, 202613-Year-old Raji Doshi named America's Top Young Scientist for inventing an algae-aragonite alkalinity system to reduce CO2-driven ocean acidification
3M named 8th grader Raji Doshi the 2026 Young Scientist Challenge winner for her algae-aragonite system to reduce ocean acidification. She received a $25,000 prize and the title of America's Top Young Scientist. Her project demonstrated how natural buffers can remove carbon dioxide from seawater.
Read more →-MMM
Oct 6, 20263M Announces Upcoming Investor Event
3M announced an upcoming investor event, specifically a third-quarter earnings conference call scheduled for October 20, 2026, at 8 a.m. CT. The call will be available via live webcast, with a replay accessible on 3M's Investor Relations website. This event highlights 3M's ongoing commitment to transparency with investors.
Read more →-MMM
Apr 21, 20263M Reports First-Quarter 2026 Results
3M Company reported its first-quarter 2026 financial results, with GAAP sales of $6.0 billion, reflecting a 1.3% increase year-on-year. While adjusted EPS rose by 14% to $2.14, GAAP EPS fell 40% from the previous year to $1.23. The company maintained a strong operating margin of 23.8% and reiterated its full-year guidance amidst a challenging market environment. 3M emphasized its commitment to executing its value creation framework to enhance business resilience and growth.
Read more →-MMM
Jan 20, 2026▼ -7%on this newsshared move
3M Reports Fourth-Quarter and Full-Year 2025 Results Initiates Full-Year 2026 Financial Guidance
3M reported its fourth-quarter and full-year results for 2025, highlighting a 2.1% year-on-year increase in GAAP sales to $6.1 billion, but a decline in operating margin by 510 basis points to 13%. Adjusted EPS rose to $1.83, up 9% compared to the previous year. The company expects 2026 to show adjusted total sales growth of 4%, with earnings per share projected between $8.50 and $8.70. Despite ongoing challenges, the leadership remains optimistic about future growth and financial commitments.
Read more →-MMM
Oct 21, 2025▲ +7.7%on this news
3M Delivers Strong Third-Quarter Results Increases Full-Year Margin and EPS Guidance
3M reported its third-quarter results for 2025, showcasing a 3.5% increase in GAAP sales to $6.5 billion, but a decline of 38% in GAAP EPS to $1.55. Adjusted EPS saw a 10% growth, reaching $2.19, while the adjusted operating margin improved to 24.7%. The company has increased its full-year EPS guidance, expressing confidence in meeting strategic and financial commitments despite ongoing risks including PFAS-related litigation. Overall, the results reflect positive operational performance even amidst legal challenges.
Read more →-MMM
Jul 18, 20253M Reports Second-Quarter 2025 Results, Increases Full-Year EPS Guidance
3M reported its second-quarter results for 2025, indicating a GAAP sales growth of 1.4% to $6.3 billion and an adjusted EPS increase of 12% to $2.16. Despite the growth in adjusted EPS, the company saw a significant decline of 38% in GAAP EPS compared to the previous year. The updated guidance for adjusted EPS reflects confidence in the company's performance, projecting a range of $7.75 to $8.00 for the year. However, the operating margin revealed a drop due to increased costs from litigation and ongoing adjustments related to tariffs.
Read more →-MMM
Apr 22, 2025▲ +8.1%on this news
3M Reports First-Quarter 2025 Results
3M (MMM) reported its first-quarter 2025 financial results, showcasing a GAAP sales figure of $6.0 billion, representing a 1.0% decline compared to the previous year. Despite this sales drop, the company reported a significant increase in earnings per share (EPS), soaring by 61% to reach $2.04, driven by improved operating margins and strong adjusted financial performance. The company also highlighted an organic sales growth of 1.5% and an adjusted operating margin increase to 23.5%. However, there were concerns regarding operating cash flow, which came in negative at $(0.1) billion.
Read more →-MMM
Jan 21, 20253M Reports Fourth-Quarter and Full-Year 2024 Results Initiates Full-Year 2025 Financial Guidance
3M reported its fourth-quarter and full-year 2024 results, highlighting a slight increase in Q4 sales to $6.0 billion, driven by a 2.1% increase in organic growth. The company also returned $3.8 billion to shareholders while providing an optimistic financial outlook for 2025, anticipating adjusted sales growth of 0.5-1.5%. Despite these positives, full-year sales saw a slight decline and adjusted EPS fell in Q4, along with ongoing concerns related to legal liabilities over PFAS products.
Read more →-MMM
Oct 22, 2024M Reports Third-Quarter Results Raises Full-Year 2024 Earnings Guidance Sales of $6.3 billion, up 0.4% YoY Adjusted sales of $6.1 billion with organic growth up 1.0% YoY GAAP EPS from continuing operations of $2.48, up 1
3M reported its third-quarter financial results, showcasing significant growth in earnings with a GAAP EPS of $2.48, up 154% compared to the previous year. Adjusted sales rose 1.5% year-on-year, leading the company to raise its full-year adjusted EPS guidance to between $7.20 and $7.30. However, operating cash flow was negative due to litigation costs, and the company recorded a small decline in organic sales. The report indicates a commitment to ongoing operational improvements and shareholder value creation.
Read more →-MMM
Jul 26, 2024▲ +23%on this news
M Delivers Strong Second-Quarter Results Company Updates Full-Year 2024 Earnings Guidance Sales of $6.3 billion, down 0.5% YoY Adjusted sales of $6.0 billion with organic growth up 1.2% YoY GAAP EPS from continuing opera
3M reported strong second-quarter results with sales of $6.3 billion, a slight decrease of 0.5% year-on-year. The company posted a GAAP EPS from continuing operations of $2.17, marking a significant increase of 117% YoY. Additionally, 3M's adjusted EPS rose by 39% YoY to $1.93. The firm updated its 2024 earnings guidance, reflecting positive operational execution, while acknowledging challenges in total sales and ongoing litigation costs related to PFAS products.
Read more →-MMM
Jun 13, 2024M transfers a portion of U.S. pension payment obligations St. Paul, Minn.
3M has announced the transfer of approximately $2.5 billion in U.S. pension payment obligations to Metropolitan Tower Life Insurance Company, affecting around 23,000 retirees. The contract, which involves no additional funding from 3M, will be activated on October 1, 2024, ensuring that monthly benefits for those retirees remain unchanged. However, 3M anticipates a non-cash pension settlement charge between $0.8 billion and $0.9 billion, which will not impact adjusted net income or cash flow for the second quarter or full year of 2024. This restructuring decision does not influence current employees and aims to streamline the pension management process.
Read more →-MMM
Apr 30, 2024M First-Quarter Results Driven by Strong Operational Performance Company Initiates Full-Year 2024 Guidance Reflecting Completion of Solventum Spin Company delivers strong first quarter results - Sales of $8.0 billion, do
3M reported its first-quarter results, showing a sales figure of $8 billion, reflecting a minor decline of 0.3% compared to the previous year. The company achieved a double-digit growth in adjusted earnings per share, reaching $2.39, which is a 21% increase year-on-year. Notably, 3M completed its spin-off of Solventum, marking a significant strategic shift, and finalized major legal settlements worth billions. The company has also initiated its full-year 2024 earnings outlook, taking into account the new structure following the spin-off.
Read more →-MMM
Apr 1, 2024▲ +6%on this news
M Completes Spin-off of Solventum
3M has completed the spin-off of its health care business, establishing Solventum Corporation as an independent entity listed on the New York Stock Exchange. Shareholders of 3M received shares of Solventum in a ratio of one share for every four shares held, with the transaction intended to be tax-free for U.S. federal income tax purposes. 3M retained a 19.9% share in Solventum, which it plans to monetize over the next five years. The company looks forward to both firms innovating and creating value in their respective markets.
Read more →-MMM
Jan 29, 2024Combat Arms Earplugs Settlement Set to Exceed 98% Participation Milestone 3M has elected to pay $1 billion in cash, instead of stock St. Paul, Minn.
3M has announced that the participation in the settlement for the Combat Arms Earplugs litigation is expected to surpass 98% by the registration deadline of March 25, 2024. The company opted to pay $1 billion in cash instead of stock as part of a larger $6 billion settlement plan that spans multiple years. This move reflects strong support from claimants, with over 250,000 eligible participants. While this settlement aims to resolve a significant number of claims, there are ongoing risks related to legal proceedings and participation rates that could affect the outcome.
Read more →-MMM
Jan 23, 2024▼ -11%on this news
M Delivers Strong Fourth-Quarter Results Improves Operational Performance and Exceeds Earnings and Cash Flow Expectations Results reflect strong operational execution, progress on restructuring, and spending discipline W
3M reported its fourth-quarter and full-year results for 2023, highlighting strong operational execution and improved earnings despite facing significant legal challenges. The company achieved an adjusted earnings per share of $2.42 for Q4, up from $2.18 the previous year, and is optimistic about continued performance improvements in 2024. Notably, the anticipated Health Care spin is on track for the first half of the year. However, sales have declined year-on-year, primarily due to ongoing market challenges and litigation settlements impacting profitability.
Read more →-MMM
Oct 24, 2023▲ +5.3%on this news
M Reports Third Quarter 2023 Results Company Increases Full Year Adjusted Earnings and Cash Flow Expectations Q3 results reflect strong operational execution, restructuring actions, and proactive spending discipline Prog
3M reported its third-quarter results for 2023, revealing a GAAP loss per share of $3.74 due to substantial settlement costs related to litigation. However, the company's adjusted earnings per share increased to $2.68, driven by strong operational execution and proactive financial management. 3M has raised its full-year adjusted EPS and cash flow expectations as a result of this performance. The company is also progressing on its Health Care spin-off, set to complete in the first half of 2024, while addressing legal matters including settlements related to PFAS claims.
Read more →-MMM
Aug 29, 2023M Announces Combat Arms Settlement St. Paul, Minn.
3M has announced a $6.0 billion settlement agreement to resolve litigation related to its Combat Arms Earplug products. The settlement is structured to include $5.0 billion in cash and $1.0 billion in common stock, and aims to cover all claims in current and potential future lawsuits. While the agreement promotes claimant participation, it does not admit to any liability and involves a substantial pre-tax charge for the company. 3M is also pursuing insurance recovery efforts to mitigate the financial impact of the settlement.
Read more →About 3M Company
Headquarters3M CENTER, ST PAUL, MN, 55144-1000
BIOPHARMAWATCH ELITE PLUS
Trade the next MMM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime